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Abstract
Background: Coxiella burnetii causes the common worldwide zoonotic infection, Q fever. It has been previously
suggested that patients who had recovered from acute Q fever (whether symptomatic or otherwise) may be at increased
risk of ischaemic heart disease. We undertook this study to determine if past infection with Coxiella burnetii, the
aetiological agent of Q fever, is a risk factor for the subsequent development of ischaemic heart disease.
Methods: A nested case-control study within the Prospective Epidemiological Study of Myocardial Infarction (PRIME). The
PRIME study is a cohort study of 10,593 middle-aged men undertaken in France and Northern Ireland in the 1990s. A
total of 335 incident cases of ischaemic heart disease (IHD) were identified and each case was matched to 2 IHD free
controls. Q fever seropositivity was determined using a commercial IgG ELISA method.
Results: Seroprevalence of Q fever in the controls from Northern Ireland and France were 7.8% and 9.0% respectively.
No association was seen between seropositivity and age, smoking, lipid levels, or inflammatory markers. The unadjusted
odds ratio (95% CI) for Q fever seropositivity in cases compared to controls was 0.95 (0.59, 1.57). The relationship was
substantially unaltered following adjustment for cardiovascular risk factors and potential confounders.
Conclusion: Serological evidence of past infection with C. burnetii was not found to be associated with an increased risk
of IHD.
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Background
Q fever is a globally distributed, common, zoonotic infec-
tion caused by the bacteria Coxiella burnetii. A large pro-
portion of cases of C. burnetii infection are asymptomatic.
Where symptomatic infection occurs, typical signs and
associated symptoms are headache, pyrexia, and respira-
tory tract infection including atypical pneumonia. Hepati-
tis may also occur. Chronic infection is well recognised,
usually in the form of Q fever endocarditis.
Various seroepidemiological and molecular biology
approaches have suggested a potential role of various viral
and bacterial infections in the development of atheroscle-
rosis. In this context it has been previously suggested that
patients who recover from acute Q fever (whether symp-
tomatic or otherwise) may be at increased risk of ischae-
mic heart disease(IHD)[1,2]. The first of these studies was
a retrospective case-control study, a study design that is
subject to several important biases including difficulty in
ascertaining the temporality of relationships, and the sec-
ond has been criticised for failing to adjust for important
confounders[3]. Until now no prospective studies have
examined this issue. We present a prospective investiga-
tion, examining the relationship between C. burnetii sero-
positivity and incident cardiovascular disease in a large
cohort study of middle aged men.
Methods
Study design
The study was a nested case-control study within the Pro-
spective Epidemiological Study of Myocardial Infarction
(PRIME) study, which is a cohort study of middle-aged
men in France and Northern Ireland (Belfast). The origi-
nal purpose of this study was to investigate the relative
roles of various risk factors on the development of ischae-
mic heart disease. Recruitment and examination methods
have been fully described previously [4,5] but are briefly
summarised here. A total of 10,593 men aged between
50–59 years were recruited from industry, various
employment groups and general practices in Lille, Stras-
bourg, Toulouse and Belfast between 1991 and 1993. The
sample was recruited to broadly match the social class
structure of the background population. Each subject
completed self-administered questionnaires on demo-
graphic, socio-economic factors and dietary habits after
informed consent was obtained. Their responses were
checked by medical staff and additional data collected
during clinic attendance on educational level, occupa-
tional activity, personal and family history, tobacco and
alcohol consumption, and physical activity. The London
School of Hygiene and Tropical Medicine Cardiovascular
(Rose) Questionnaire for Chest Pain on Effort and Possi-
ble Infarction [6] was also administered.
Clinical examination
Baseline investigations included a standard 12-lead elec-
trocardiogram and standardised blood pressure measure-
ments (measured on 2 occasions in the sitting position)
using an automatic sphygmomanometer (Spengler SP9).
Anthropometric measurements included height and
weight without shoes and waist and hip circumferences.
Subjects were considered to have a history of IHD at entry
if they had one of the following: myocardial infarction
(MI) and/or angina pectoris diagnosed by a physician,
electrocardiographic evidence of MI, or a positive answer
to the Rose questionnaire. There were 9,758 subjects with-
out a history of IHD at entry into the study.
Case-control selection and follow-up
Subjects were contacted annually by letter and asked to
complete a clinical event questionnaire. Phone contact
was established with non-responders or their general
practitioner. Coronary cases were defined as the presence
of at least one of the following: non-fatal MI, death from
IHD, or angina pectoris. Five-year follow-up has been
completed (98% follow-up was achieved). The total
number of incident IHD cases identified was 335. Each
case was matched to 2 controls, who were study partici-
pants of the same age (± 3 years) recruited in the same
centre on the same day (± 2 days) as the corresponding
case and were free of IHD on the date of the ischaemic
event of the case.
Laboratory methods
Baseline venous blood samples were collected at the start
of the study after a 12 hour fast and centrifuged within 4
hours. All assays were performed blind to the investigat-
ing centre and by consecutive number so that samples
from all 4 centres were included in each analytical run. All
procedures were standardised between centres. Among
other measurements, total and HDL cholesterol, triglycer-
ides, and fibrinogen were assayed at recruitment on all
subjects. C-reactive protein (CRP) and interleukin 6 (IL-6)
were assayed on stored samples from cases and controls.
Enzymatic methods were employed to measure total cho-
lesterol and triglycerides using a commercial kit in an
automatic analyser (Boehringer Mannheim, Germany).
HDL cholesterol was measured by an enzymatic method
(Boehringer Mannheim, Germany) after precipitation
using phosphotungstate magnesium chloride. LDL cho-
lesterol was calculated according to Friedewald and col-
leagues [7] Fibrinogen was measured according to the
method of Clauss[8] High sensitivity CRP was measured
by immunonephelometry (hs-CRP: Dade Behring, Reuil-
Malmaison, France). IL-6 was measured by ELISA (R&D,
Europe).BMC Infectious Diseases 2005, 5:61 http://www.biomedcentral.com/1471-2334/5/61
Page 3 of 5
(page number not for citation purposes)
Q fever ELISA testing
The presence of IgG antibodies to Phase II C. burnetii in
the baseline serum specimen was performed using a com-
mercially available indirect ELISA test kit (Vircell, Gra-
nada, Spain. Cat. No. G1001). The standard
manufacturer's protocol was followed for testing, use of
controls, and interpretation The antigen used in the Vir-
cell IgG assay is C. burnetii phase II Nine Mile, grown in
cell culture. The cut off for a positive test result was based
on the manufacturers stipulated guidelines. Provided that
Optical Densities (OD) for positive, negative and cut off
controls fell within the manufacturers stated guidelines
the test was considered valid. The mean OD for cut off
serum was determined. An antibody index was then deter-
mined for each sample tested Antibody Index = (sample
OD/cut off serum mean OD) × 10. The results were then
interpreted in line with the manufacturer's guidance as
follows: <9 Negative; 9–11 Equivocal; >11 Positive.
Statistical methods
Smoking status was categorised as never smoked, ex-
smoker, or current smoker of <20 or = 20 cigarettes a day.
Alcohol intake was calculated in grams per week and cat-
egorised into none, <225 g/week and = 225 g/week. The
following skewed variables were log transformed before
inclusion in analyses: triglycerides, CRP, and IL-6. Equiv-
ocal Q fever results were treated as seropositive (n = 3). In
the controls, Chi-square tests and t-tests were used to
examine the differences in prevalence of Q fever seropos-
itivity between Northern Irish and French subjects, the
relationship between seropositivity and age and smoking
status, and between seropositivity and lipid levels and
markers of inflammation (fibrinogen, CRP and IL-6).
Conditional (matched) logistic regression analysis was
used to examine the relationship between Q fever serop-
ositivity and case-control status. The relationship was
adjusted for age, smoking, body mass index, systolic and
diastolic blood pressure, social class, physical activity, and
alcohol intake at baseline. Further adjustment was under-
taken for lipids (total cholesterol, HDL cholesterol and
triglycerides) and then for markers of inflammation.
Finally, a country/Q fever seropositivity interaction term
was entered into the model. All analyses were performed
using Stata version 8.
Table 1: Relationships between seropositivity for Q fever and characteristics of control subjects
Mean (SD) p-value
Seronegative Seropositive
Age (years) 55.2 (2.69) 54.9 (3.11) 0.45
Total cholesterol 2.23 (0.42) 2.15 (0.31) 0.20
HDL 0.48 (0.12) 0.48 (0.15) 0.69
Triglycerides* 1.37 (1.72) 1.35 (1.68) 0.81
Fibrinogen 3.37 (0.98) 3.53 (1.10) 0.16
CRP* 1.39 (2.73) 1.32 (2.01) 0.76
IL-6* 1.53 (1.97) 1.39 (2.73) 0.14
Number (%) Number (%)
Smoking never smoked 223 (25.8) 14 (18.2)
ex-smoker 360 (41.6) 38 (49.4)
current smoker < 20/day 164 (18.9) 11 (14.3)
current smoker ≥ 20/day 118 (13.6) 14 (18.2) 0.21
* geometric mean
Table 2: Unadjusted and adjusted relationships between Q fever seropositivity and case-control status.
Unadjusted odds ratio (95% CI) Adjusted odds ratio1 (95% CI) Adjusted odds ratio2 (95% CI) Adjusted odds ratio3 (95% CI)
Q fever status
Seronegative 1.00 (reference category) 1.00 (reference category) 1.00 (reference category) 1.00 (reference category)
Seropositive 0.95 (0.57 1.57) 0.96 (0.56, 1.64) 1.04 (0.59, 1.82) 1.20 (0.66, 2.18)
1 adjusted for age, smoking, body mass index, systolic and diastolic blood pressure, social class, physical activity, and alcohol intake
2 further adjustment for total cholesterol, HDL cholesterol, and triglycerides
3 further adjustment for fibrinogen, CRP, and IL-6BMC Infectious Diseases 2005, 5:61 http://www.biomedcentral.com/1471-2334/5/61
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Ethical approval was obtained from the Queen's Univer-
sity of Belfast Ethical Committee
Results
Serum was available for Q fever testing from 320 (95.5%)
of the 335 cases and 622 (92.8%) of 670 controls. Q fever
results were available for the case and at least one control
in 317 cases (94.6%). Among the controls, there was no
difference in the seroprevalence of Q fever antibodies
between Northern Ireland and France; 7.8% and 9.0%
seropositive respectively. Within France, 12.4% of con-
trols from Toulouse were seropositive, while seropositiv-
ity in the other 2 centres was 7.0% (χ2 = 2.99, df 1, p =
0.08). There was no difference in age between seroposi-
tives and seronegatives; mean age (SD) was 54.9 years
(3.11) and 55.2 years (2.69) respectively. No association
was seen between seropositivity and age, smoking, lipid
levels, or inflammatory markers (Table 1).
The unadjusted and adjusted relationships between Q
fever seropositivity and case-control status are shown in
Table 2. The odds of Q fever seropositivity in cases com-
pared to controls was not elevated, either before or after
adjustment for the baseline variables age, smoking, body
mass index, systolic and diastolic blood pressure, social
class, physical activity, and alcohol intake. Further adjust-
ment for lipids also had little effect on observed odds
ratios. The relationship strengthened slightly on adjusting
for the inflammatory markers fibrinogen, CRP and IL-6,
but was not statistically significant. A country/Q fever
seropositivity interaction term was not significant when
added to the fully adjusted model.
Discussion
Atheroma is an inflammatory condition which has been
putatively associated with infections including a range of
bacterial infections. Against this background it has been
suggested that the long-term sequelae of C. burnetii infec-
tion may include an elevated risk of cardiovascular dis-
ease[1,2]. Original tentative suggestions of a link were in
the form of a case report of acute MI in a patient with Q
fever infection[9]. More recently Enders et al. have sug-
gested that C. burnetii infection may have a modest asso-
ciation with coronary artery disease. This is based on the
evaluation of 155 consecutive patients undergoing coro-
nary angiography using C. burnetii serology[1] Further
positive associations have been reported in a follow-up
study of people infected in 1983 in a large outbreak of Q
fever in Switzerland[10] However this study was criticised
for not controlling for current and past cigarette smoking
as a potential explanation for the excess cardiovascular
morbidity and mortality observed[3]. In this nested case-
control study we were able to adjust for smoking and a
range of other potential confounders, but this adjustment
had little effect on observed odds ratios. We did not find
any association between serological evidence of prior Q-
fever infection and incident IHD. However, it is possible
that selection/survivor bias may have occurred to some
extent in the study. People with more severe Q fever infec-
tions, who may be more likely to develop some arterial
disease if an association exists, may not have been
enrolled in the study because of illness or death. In the
Swiss study acute Q fever was found to be associated more
closely with stroke than with myocardial infartion, how-
ever the stroke outcome could not be tested in our study.
The reported chronic fatigue syndrome associated with Q
fever appears not to be associated with cardiac disease.
[11]
Smoking
Previous literature has suggested an association between
smoking status and Q fever. In a large outbreak of Q fever
pneumonia in Birmingham, UK in 1989, 60 (55%) of 110
patients for whom smoking data were available were cur-
rent smokers, 28 (25%) were ex-smokers, and only 22
(20%) had never smoked[3]. A subsequent case-control
study in the same cohort demonstrated smoking to be a
risk factor for Q fever[12] Smoking was also shown to be
an independent risk factor for acquisition of Q fever infec-
tion in goat workers in rural Newfoundland[13] Several
possible explanations exist for these findings. Smoking
may reflect the extent of hand to mouth contact which
may be important in transmission of the infection, espe-
cially in an occupational exposure setting. Alternatively,
smokers may be more likely to get symptomatic rather
than asymptomatic disease. Our finding of no association
between smoking status and seroprevalence would tend
to favour the second explanation, assuming that the
reported association with smoking and symptomatic Q
fever is valid. Alternatively, an explanation of our finding
is that that there is no increased risk of infection, either
silent or clinical, in smokers.
Geographic differences
Differences in seroprevalence between Northern Ireland
and France might have been expected, as they are very dif-
ferent in terms of topography and farming practice. How-
ever, the cohort recruitment methods employed in both
countries were likely to exclude farmers. There was some
evidence of higher prevalence in the southern French cen-
tre compared to the other centres, although conventional
statistical significance was not achieved. An overall sero-
prevalence figure of almost 10% in populations not
known to be occupationally exposed to Q fever testifies to
the ubiquity of infection with this zoonotic agent in
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Conclusion
This prospective study did not find any association
between serological evidence of past infection with C. bur-
netii and IHD.
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